Topical Skin Infection Treatment Market Growth Analysis - Forecast Trends, Market Size, Share and Outlook (2025-2034)
Description
The topical skin infection treatment market was valued at USD 15.60 Billion in 2024 driven by the rising drug approvals to treat the condition across the 8 major markets. The market is anticipated to grow at a CAGR of 5.20% during the forecast period 2025-2034 to reach a value of USD 25.90 Billion by 2034.
Topical Skin Infection Treatment Market Overview
Skin infection is a medical condition when the skin gets infected by foreign bodies such as bacteria, viruses, fungi, or parasites. Skin infections can result in mild to severe itching, skin flaking, inflammation, redness, and other symptoms, leaving patients with utter discomfort. If not treated on time some skin infections can turn fatal. Topical skin infection treatment includes medicated gels, ointments, and powders, among other products, basically applied on the surface of the skin, unlike oral medications.
Topical Skin Infection Treatment Market Growth Drivers
Rising Prevalence of Skin Infections
The market growth can be attributed to the increasing prevalence of skin infections. For instance, the World Health Organization estimated that nearly 1.8 billion people will suffer from skin conditions at any point in time. Skin conditions are most common in tropical areas and include skin infections that are bacterial, viral, fungal, or parasitic in origin. In most communities, skin-related neglected tropical diseases (NTDs) form about 10% of skin diseases. Additionally, the emergence of new and more threatening skin infections is further poised to boost the market for topical skin infection treatments.
Rising FDA Clearances to Meet Rising Topical Skin Infection Treatment Market Demand
As the prevalence of several skin infections is increasing, the efforts toward introducing highly effective topical skin treatments is on the rise. In January 2024, the FDA approved Ligand Pharmaceuticals’ 10.3% berdazimer topical gel (Zelsuvmi) for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients aged 1 year and older. Molluscum contagiosum is a contagious viral skin infection that transmits through skin-to-skin contact. Regulatory authorities like the FDA are recognising the need to bring advanced and effective treatments for such infectious medical conditions, thereby, giving approvals to new formulations and treatment products. FDA approvals add credibility to new treatment innovations, contributing to increased adoption among healthcare providers and patients, and resulting in improved patient outcomes.
Additionally, in July 2024, Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company that focuses on bringing innovations in immuno-dermatology, announced the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged from 6 years and older. ZORYVE is a once-daily, steroid-free cream developed to be a treatment option for long-term disease control that provides rapid treatment of the infection and significantly reduces itching.
Rising Research Initiatives to Build Innovative Products
A research article published in December 2023, concluded that turpentine larch, and eucalyptus oil, reduce a substantial number of follicle lesions and promote the healing of folliculitis. Folliculitis is a dreadful infection in which the patient suffers from inflammation of the hair follicles that is mostly caused by bacterial, fungal, or, more rarely, viral infections. The use of turpentine has also been found to be used in the traditional practice of treating various skin infections. The conclusion of the clinical trial was based on seventy outpatients with acute folliculitis who were treated with turpentine ointment. This clinical trial may contribute to the development of innovative turpentine-based medicated solutions effective in treating folliculitis, stimulating market expansion.
Topical Skin Infection Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Key Trends Impact
Rising Prevalence of Skin Conditions The rising prevalence of skin conditions across the globe is contributing to increasing demand for topical skin infection treatment, bolstering market growth.
Increased Focus on Topical Treatments the market is highly influenced by the escalating preference for topical treatments over traditional oral medication as they have comparatively low chances of side effects. The rising preference is leading the market growth.
Rising Awareness Around Skin Infections the market is witnessing a significant increase in awareness about skin health and infection prevention, leading to early diagnosis and treatments, and propelling market demand.
Advancements in Anti-Microbial Agents the market is influenced by the development of new antibiotics and antifungal medications targeting resistant strains and improving the efficacy of the medication.
Topical Skin Infection Treatment Market Segmentation
Market Breakup by Product Type
Market Segmentation Based on Product Type to Witness Growth
The market segmentation by product type includes cream, gel, lotion, powders, and others. The market share is led by creams due to their effectiveness and easy-to-use options. Creams are suitable for various skin types and infections working both as a hydrating agent and medication.
The easy application and availability of OTC ointments are major factors driving the growth of this segment.
Segmentation by Distribution Channel Dominating the Market Share
The market segmentation by distribution channel includes hospital pharmacies, independent pharmacies, online pharmacies, and others. The segment is led by hospital pharmacies due to the critical role hospitals play in treating severe skin infections. Patients often require immediate access to specialised medications, which are more readily available in hospital settings. This factor is responsible for the dominance of hospitals in the market share.
Topical Skin Infection Treatment Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, India, and Japan. The United States leads the market due to its advanced healthcare infrastructure along with the high prevalence of skin infections in the region. Increasing awareness about skin health and investments in research and development are leading to the introduction of innovative effective treatment options. There is a substantially high demand for over-the-counter (OTC) products and their easy availability, filling the crucial demand-supply chain are bolstering market demand and growth. The regional dominance is further attributed to the presence of key market players bringing innovative treatment products into the market.
Leading players in the Topical Skin Infection Treatment Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Mölnlycke Health Care AB
Mölnlycke Health Care AB specialises in advanced wound care and surgical solutions, with a strong focus on treating topical skin infections. Their portfolio includes innovative dressings and antiseptic products designed to manage wounds, reduce infection risks, and promote healing.
Coloplast Corp
Coloplast Corp offers a comprehensive range of products targeting skin infections, particularly within their wound and skin care division. Their portfolio includes advanced dressings, cleansers, and protective barriers that support infection prevention and effective treatment.
Johnson and Johnson, Inc.
Johnson & Johnson's portfolio for topical skin infection treatment includes a variety of over-the-counter antiseptics, wound care products, and medicated creams. Their focus is on providing accessible and effective solutions for managing and treating skin infections.
Other key players in the market include Smith+Nephew, Convatec Inc., Cardinal Health, Dynarex Corporation, MIMEDX Group Inc., and 3M.
Key Questions Answered in the Topical Skin Infection Treatment Market
Topical Skin Infection Treatment Drug Pipeline Analysis Report
Topical Skin Infection Treatment Market Overview
Skin infection is a medical condition when the skin gets infected by foreign bodies such as bacteria, viruses, fungi, or parasites. Skin infections can result in mild to severe itching, skin flaking, inflammation, redness, and other symptoms, leaving patients with utter discomfort. If not treated on time some skin infections can turn fatal. Topical skin infection treatment includes medicated gels, ointments, and powders, among other products, basically applied on the surface of the skin, unlike oral medications.
Topical Skin Infection Treatment Market Growth Drivers
Rising Prevalence of Skin Infections
The market growth can be attributed to the increasing prevalence of skin infections. For instance, the World Health Organization estimated that nearly 1.8 billion people will suffer from skin conditions at any point in time. Skin conditions are most common in tropical areas and include skin infections that are bacterial, viral, fungal, or parasitic in origin. In most communities, skin-related neglected tropical diseases (NTDs) form about 10% of skin diseases. Additionally, the emergence of new and more threatening skin infections is further poised to boost the market for topical skin infection treatments.
Rising FDA Clearances to Meet Rising Topical Skin Infection Treatment Market Demand
As the prevalence of several skin infections is increasing, the efforts toward introducing highly effective topical skin treatments is on the rise. In January 2024, the FDA approved Ligand Pharmaceuticals’ 10.3% berdazimer topical gel (Zelsuvmi) for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients aged 1 year and older. Molluscum contagiosum is a contagious viral skin infection that transmits through skin-to-skin contact. Regulatory authorities like the FDA are recognising the need to bring advanced and effective treatments for such infectious medical conditions, thereby, giving approvals to new formulations and treatment products. FDA approvals add credibility to new treatment innovations, contributing to increased adoption among healthcare providers and patients, and resulting in improved patient outcomes.
Additionally, in July 2024, Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company that focuses on bringing innovations in immuno-dermatology, announced the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged from 6 years and older. ZORYVE is a once-daily, steroid-free cream developed to be a treatment option for long-term disease control that provides rapid treatment of the infection and significantly reduces itching.
Rising Research Initiatives to Build Innovative Products
A research article published in December 2023, concluded that turpentine larch, and eucalyptus oil, reduce a substantial number of follicle lesions and promote the healing of folliculitis. Folliculitis is a dreadful infection in which the patient suffers from inflammation of the hair follicles that is mostly caused by bacterial, fungal, or, more rarely, viral infections. The use of turpentine has also been found to be used in the traditional practice of treating various skin infections. The conclusion of the clinical trial was based on seventy outpatients with acute folliculitis who were treated with turpentine ointment. This clinical trial may contribute to the development of innovative turpentine-based medicated solutions effective in treating folliculitis, stimulating market expansion.
Topical Skin Infection Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Key Trends Impact
Rising Prevalence of Skin Conditions The rising prevalence of skin conditions across the globe is contributing to increasing demand for topical skin infection treatment, bolstering market growth.
Increased Focus on Topical Treatments the market is highly influenced by the escalating preference for topical treatments over traditional oral medication as they have comparatively low chances of side effects. The rising preference is leading the market growth.
Rising Awareness Around Skin Infections the market is witnessing a significant increase in awareness about skin health and infection prevention, leading to early diagnosis and treatments, and propelling market demand.
Advancements in Anti-Microbial Agents the market is influenced by the development of new antibiotics and antifungal medications targeting resistant strains and improving the efficacy of the medication.
Topical Skin Infection Treatment Market Segmentation
Market Breakup by Product Type
- Creams
- Gel
- Lotions
- Powder
- Others
- Antibiotics
- Antiseptics
- Primary Infection
- Secondary Infection
- Hospitals and Clinics
- Homecare Settings
- Ambulatory Surgical Centers
- Others
- Hospital Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Product Type to Witness Growth
The market segmentation by product type includes cream, gel, lotion, powders, and others. The market share is led by creams due to their effectiveness and easy-to-use options. Creams are suitable for various skin types and infections working both as a hydrating agent and medication.
The easy application and availability of OTC ointments are major factors driving the growth of this segment.
Segmentation by Distribution Channel Dominating the Market Share
The market segmentation by distribution channel includes hospital pharmacies, independent pharmacies, online pharmacies, and others. The segment is led by hospital pharmacies due to the critical role hospitals play in treating severe skin infections. Patients often require immediate access to specialised medications, which are more readily available in hospital settings. This factor is responsible for the dominance of hospitals in the market share.
Topical Skin Infection Treatment Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, India, and Japan. The United States leads the market due to its advanced healthcare infrastructure along with the high prevalence of skin infections in the region. Increasing awareness about skin health and investments in research and development are leading to the introduction of innovative effective treatment options. There is a substantially high demand for over-the-counter (OTC) products and their easy availability, filling the crucial demand-supply chain are bolstering market demand and growth. The regional dominance is further attributed to the presence of key market players bringing innovative treatment products into the market.
Leading players in the Topical Skin Infection Treatment Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Mölnlycke Health Care AB
Mölnlycke Health Care AB specialises in advanced wound care and surgical solutions, with a strong focus on treating topical skin infections. Their portfolio includes innovative dressings and antiseptic products designed to manage wounds, reduce infection risks, and promote healing.
Coloplast Corp
Coloplast Corp offers a comprehensive range of products targeting skin infections, particularly within their wound and skin care division. Their portfolio includes advanced dressings, cleansers, and protective barriers that support infection prevention and effective treatment.
Johnson and Johnson, Inc.
Johnson & Johnson's portfolio for topical skin infection treatment includes a variety of over-the-counter antiseptics, wound care products, and medicated creams. Their focus is on providing accessible and effective solutions for managing and treating skin infections.
Other key players in the market include Smith+Nephew, Convatec Inc., Cardinal Health, Dynarex Corporation, MIMEDX Group Inc., and 3M.
Key Questions Answered in the Topical Skin Infection Treatment Market
- What was the topical skin infection treatment market value in 2024?
- What is the topical skin infection treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on product type?
- What is market segmentation based on type?
- What is market breakup based on category?
- What is the market segmentation based on distribution channels?
- Who are the end-users in the market?
- What are the major factors aiding the demand for topical skin infection treatment in the market?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major topical skin infection treatment market trends?
- Which distribution channel is expected to dominate the market?
- Which product type will dominate the market share?
- Which end-user will lead the market?
- Who are the key players involved in the topical skin infection treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Topical Skin Infection Treatment Drug Pipeline Analysis Report
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Topical Skin Infection Treatment Market Overview – 8 Major Markets
- 3.1 Topical Skin Infection Treatment Market Historical Value (2018-2024)
- 3.2 Topical Skin Infection Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Topical Skin Infection Treatment Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Topical Skin Infection Treatment Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU-4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 U.S.
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU-4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment seeking rate, by Country
- 7.1.3.1 U.S.
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU-4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Topical Skin Infection Treatment Market Landscape – 8 Major Markets
- 8.1 Topical Skin Infection Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Topical Skin Infection Treatment Market: Product Landscape
- 8.2.1 Analysis by Product Type
- 8.2.2 Analysis by Type
- 8.2.3 Analysis by Category
- 9 Topical Skin Infection Treatment Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Topical Skin Infection Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Topical Skin Infection Treatment Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Topical Skin Infection Treatment Market (2018-2034) by Product Type
- 12.1.1 Market Overview
- 12.1.2 Creams
- 12.1.3 Gel
- 12.1.4 Lotions
- 12.1.5 Powder
- 12.1.6 Others
- 12.2 Topical Skin Infection Treatment Market (2018-2034) by Category
- 12.2.1 Market Overview
- 12.2.2 Antibiotics
- 12.2.3 Antiseptics
- 12.3 Topical Skin Infection Treatment Market (2018-2034) by Type
- 12.3.1 Market Overview
- 12.3.2 Primary Infection
- 12.3.3 Secondary Infection
- 12.4 Topical Skin Infection Treatment Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals & Clinics
- 12.4.3 Homecare Settings
- 12.4.4 Ambulatory Surgical Centers
- 12.4.5 Others
- 12.5 Topical Skin Infection Treatment Market (2018-2034) by Distribution Channel
- 12.5.1 Market Overview
- 12.5.2 Hospital Pharmacies
- 12.5.3 Independent Pharmacies
- 12.5.4 Online Pharmacies
- 12.5.5 Others
- 12.6 Topical Skin Infection Treatment Market (2018-2034) by Region
- 12.6.1 Market Overview
- 12.6.2 United States
- 12.6.3 EU-4 and the United Kingdom
- 12.6.3.1 Germany
- 12.6.3.2 France
- 12.6.3.3 Italy
- 12.6.3.4 Spain
- 12.6.3.5 United Kingdom
- 12.6.4 India
- 12.6.5 Japan
- 13 United States Topical Skin Infection Treatment Market (218-2034)
- 13.1 United States Topical Skin Infection Treatment Market Historical Value (2018-2024)
- 13.2 United States Topical Skin Infection Treatment Market Forecast Value (2025-2034)
- 13.3 United States Topical Skin Infection Treatment Market (2018-2034) by Product Type
- 13.3.1 Market Overview
- 13.3.2 Creams
- 13.3.3 Gel
- 13.3.4 Lotions
- 13.3.5 Powder
- 13.3.6 Others
- 13.4 United States Topical Skin Infection Treatment Market (2018-2034) by Category
- 13.4.1 Market Overview
- 13.4.2 Antibiotics
- 13.4.3 Antiseptics
- 13.5 United States Topical Skin Infection Treatment Market (2018-2034) by Type
- 13.5.1 Market Overview
- 13.5.2 Primary Infection
- 13.5.3 Secondary Infection
- 13.6 United States Topical Skin Infection Treatment Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals & Clinics
- 13.6.3 Homecare Settings
- 13.6.4 Ambulatory Surgical Centers
- 13.6.5 Others
- 13.7 United States Topical Skin Infection Treatment Market (2018-2034) by Distribution Channel
- 13.7.1 Market Overview
- 13.7.2 Hospital Pharmacies
- 13.7.3 Independent Pharmacies
- 13.7.4 Online Pharmacies
- 13.7.5 Others
- 14 EU-4 and United Kingdom Topical Skin Infection Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Topical Skin Infection Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Topical Skin Infection Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Topical Skin Infection Treatment Market (2018-2034) by Product Type
- 14.3.1 Market Overview
- 14.3.2 Creams
- 14.3.3 Gel
- 14.3.4 Lotions
- 14.3.5 Powder
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Topical Skin Infection Treatment Market (2018-2034) by Category
- 14.4.1 Market Overview
- 14.4.2 Antibiotics
- 14.4.3 Antiseptics
- 14.5 EU-4 and United Kingdom Topical Skin Infection Treatment Market (2018-2034) by Type
- 14.5.1 Market Overview
- 14.5.2 Primary Infection
- 14.5.3 Secondary Infection
- 14.6 EU-4 and United Kingdom Topical Skin Infection Treatment Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals & Clinics
- 14.6.3 Homecare Settings
- 14.6.4 Ambulatory Surgical Centers
- 14.6.5 Others
- 14.7 EU-4 and United Kingdom Topical Skin Infection Treatment Market (2018-2034) by Distribution Channel
- 14.7.1 Market Overview
- 14.7.2 Hospital Pharmacies
- 14.7.3 Independent Pharmacies
- 14.7.4 Online Pharmacies
- 14.7.5 Others
- 15 India Topical Skin Infection Treatment Market
- 15.1 India Topical Skin Infection Treatment Market Historical Value (2018-2024)
- 15.2 India Topical Skin Infection Treatment Market Forecast Value (2025-2034)
- 15.3 India Topical Skin Infection Treatment Market (2018-2034) by Product Type
- 15.3.1 Market Overview
- 15.3.2 Creams
- 15.3.3 Gel
- 15.3.4 Lotions
- 15.3.5 Powder
- 15.3.6 Others
- 15.4 India Topical Skin Infection Treatment Market (2018-2034) by Category
- 15.4.1 Market Overview
- 15.4.2 Antibiotics
- 15.4.3 Antiseptics
- 15.5 India Topical Skin Infection Treatment Market (2018-2034) by Type
- 15.5.1 Market Overview
- 15.5.2 Primary Infection
- 15.5.3 Secondary Infection
- 15.6 India Topical Skin Infection Treatment Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals & Clinics
- 15.6.3 Homecare Settings
- 15.6.4 Ambulatory Surgical Centers
- 15.6.5 Others
- 15.7 India Topical Skin Infection Treatment Market (2018-2034) by Distribution Channel
- 15.7.1 Market Overview
- 15.7.2 Hospital Pharmacies
- 15.7.3 Independent Pharmacies
- 15.7.4 Online Pharmacies
- 15.7.5 Others
- 16 Japan Topical Skin Infection Treatment Market
- 16.1 Japan Topical Skin Infection Treatment Market Historical Value (2018-2024)
- 16.2 Japan Topical Skin Infection Treatment Market Forecast Value (2025-2034)
- 16.3 Japan Topical Skin Infection Treatment Market (2018-2034) by Product Type
- 16.3.1 Market Overview
- 16.3.2 Creams
- 16.3.3 Gel
- 16.3.4 Lotions
- 16.3.5 Powder
- 16.3.6 Others
- 16.4 Japan Topical Skin Infection Treatment Market (2018-2034) by Category
- 16.4.1 Market Overview
- 16.4.2 Antibiotics
- 16.4.3 Antiseptics
- 16.5 Japan Topical Skin Infection Treatment Market (2018-2034) by Type
- 16.5.1 Market Overview
- 16.5.2 Primary Infection
- 16.5.3 Secondary Infection
- 16.6 Japan Topical Skin Infection Treatment Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals & Clinics
- 16.6.3 Homecare Settings
- 16.6.4 Ambulatory Surgical Centers
- 16.6.5 Others
- 16.7 Japan Topical Skin Infection Treatment Market (2018-2034) by Distribution Channel
- 16.7.1 Market Overview
- 16.7.2 Hospital Pharmacies
- 16.7.3 Independent Pharmacies
- 16.7.4 Online Pharmacies
- 16.7.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 India CDSCO
- 17.5 Japan PMDA
- 18 Patent Analysis
- 18.1 Analysis by Product Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Distribution Channel
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Product Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Product Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Mölnlycke Health Care AB
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Coloplast Corp
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 Johnson and Johnson, Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Smith+Nephew
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Convatec Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 Cardinal Health
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Dynarex Corporation
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 MIMEDX Group Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 3M
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 24 Topical Skin Infection Treatment Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
